FDA declares semaglutide shortage over, spelling end to compounded GLP-1 market, for now
The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and Wegovy, is no longer in short supply. | The demand for weight loss drugs is not slowing down,
Compounders sue FDA again over declaring end of shortage for Novo's semaglutide
Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s weight loss drugs without a fight. | Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s weight loss drugs without a fight.
A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another ...
The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...
Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback